Cover Image
市場調查報告書

進行性上眼神經核麻痺症:開發中產品分析 (2015年下半年)

Progressive Supranuclear Palsy - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 276011
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
進行性上眼神經核麻痺症:開發中產品分析 (2015年下半年) Progressive Supranuclear Palsy - Pipeline Review, H1 2016
出版日期: 2016年06月22日 內容資訊: 英文 71 Pages
簡介

由於 進行性上眼神經核麻痺症(PSP)是別名Steele-Richardson-Olszewski症候群的神經退化的難治之症,會出現平衡感覺、移動、視野、會話、吞嚥等沉重的障礙。主要的症狀,有倦怠感和頭痛、暈眩、憂鬱症、帕金森氏症,及行動、認識、步行障礙等,很快導致失衡和關節疼痛。到目前為止證明的風險要素只有年齡。主要的治療方法有抗膽鹼劑的藥物治療等。

提供著對本報告提供進行性上眼神經核麻痺症(PSP)的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等。

目錄

簡介

  • 分析範圍

進行性上眼神經核麻痺症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發治療藥的企業

  • AB Science
  • AlzProtect SAS
  • Bristol-Myers Squibb Company
  • Prana Biotechnology Limited
  • ProteoTech, Inc.
  • Sellas Inc.
  • TauRx Therapeutics Ltd.

治療藥的評估

  • 單獨療法的情況
  • 各標靶
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ASN-561
    • 產品概要
    • 作用機制 (MoA)
    • 研究開發 (R&D) 的發展情形
  • AZP-2006
  • BMS-986168
  • DC-TAB
  • DP-C016
  • mashichinibu
  • PBT-434
  • PTI-51CH3
  • PTI-51CH3 Backup
  • TPI-287
  • TRx-0237
  • 酒石酸zorupidemu

開發中產品的最新趨勢

暫停中的企劃

產品開發的里程碑

  • 最新消息和新聞稿 (共2件)

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8192IDB

Summary

Global Markets Direct's, 'Progressive Supranuclear Palsy - Pipeline Review, H1 2016', provides an overview of the Progressive Supranuclear Palsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy
  • The report reviews pipeline therapeutics for Progressive Supranuclear Palsy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Progressive Supranuclear Palsy therapeutics and enlists all their major and minor projects
  • The report assesses Progressive Supranuclear Palsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Progressive Supranuclear Palsy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Progressive Supranuclear Palsy Overview
  • Therapeutics Development
    • Pipeline Products for Progressive Supranuclear Palsy - Overview
  • Progressive Supranuclear Palsy - Therapeutics under Development by Companies
  • Progressive Supranuclear Palsy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Progressive Supranuclear Palsy - Products under Development by Companies
  • Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development
    • AB Science SA
    • AbbVie Inc.
    • AlzProtect SAS
    • Cortice Biosciences, Inc.
    • Merck & Co., Inc.
    • Otsuka Holdings Co., Ltd.
    • Prana Biotechnology Limited
    • Sellas Inc.
    • TauRx Therapeutics Ltd.
  • Progressive Supranuclear Palsy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ABBV-8E12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASN-561 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVP-786 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZP-2006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986168 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DC-TAB - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DPC-016 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • masitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-8719 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PBT-434 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Progressive Supranuclear Palsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TPI-287 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRx-0237 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • zolpidem tartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Progressive Supranuclear Palsy - Dormant Projects
  • Progressive Supranuclear Palsy - Product Development Milestones
    • Featured News & Press Releases
      • Jul 17, 2015: C2N And Abbvie Announce FDA Orphan Drug Designation Of C2N-8E12 (ABBV-8E12) For The Treatment Of Progressive Supranuclear Palsy
      • Jul 07, 2014: Cortice Announces Enrollment of a Phase 1 Clinical Trial Evaluating TPI 287 in Rare Tauopathy Diseases
      • Dec 10, 2013: Potential Treatment for Parkinson's & Parkinson-Like Diseases with Zolpidem: Sellas Life Sciences Group Holds Global Development & Marketing Rights
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Progressive Supranuclear Palsy, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Progressive Supranuclear Palsy - Pipeline by AB Science SA, H1 2016
  • Progressive Supranuclear Palsy - Pipeline by AbbVie Inc., H1 2016
  • Progressive Supranuclear Palsy - Pipeline by AlzProtect SAS, H1 2016
  • Progressive Supranuclear Palsy - Pipeline by Cortice Biosciences, Inc., H1 2016
  • Progressive Supranuclear Palsy - Pipeline by Merck & Co., Inc., H1 2016
  • Progressive Supranuclear Palsy - Pipeline by Otsuka Holdings Co., Ltd., H1 2016
  • Progressive Supranuclear Palsy - Pipeline by Prana Biotechnology Limited, H1 2016
  • Progressive Supranuclear Palsy - Pipeline by Sellas Inc., H1 2016
  • Progressive Supranuclear Palsy - Pipeline by TauRx Therapeutics Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Progressive Supranuclear Palsy - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Progressive Supranuclear Palsy, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top